Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 09 Feb 2022
TGA provisionally approves AstraZeneca's COVID-19 vaccine as booster dose
9 February 2022 - On 8 February 2022, the TGA provisionally approved a booster dose of the AstraZeneca COVID-19 vaccine, Vaxzevria, ...
Posted by Michael Wonder on 09 Feb 2022
Angelini Pharma’s Ontozry available for patients in Scotland with drug resistant epilepsy
9 February 2022 - SMC accepts promising new therapy which offers a better quality of life to patients with epilepsy ...
Posted by Michael Wonder on 09 Feb 2022
Initiation of DARWIN EU Coordination Centre advances integration of real world evidence into assessment of medicines in the EU
9 February 2022 - EMA is initiating today the establishment of the Coordination Centre for the Data Analysis and Real ...
Posted by Michael Wonder on 09 Feb 2022
A mother, shaped by tragedy, embarks on a mission to advance custom medicines
9 February 2022 - For weeks, Julia Vitarello avoided the room in her home. The fairy curtains she sewed. The ...
Posted by Michael Wonder on 09 Feb 2022
HIRA mulls therapeutic outcome based benefits for ultra-expensive drugs
9 February 2022 - Pharmaceutical industry officials are paying attention to how the Korean government will manage health insurance benefits ...
Posted by Michael Wonder on 09 Feb 2022
NICE terminates yet another appraisal of daratumumab
9 December 2022 - NICE has attempted to appraise daratumumab six times; three have had to be terminated. ...
Posted by Michael Wonder on 09 Feb 2022
Evolus receives acceptance of submission in Australia, a pivotal step in approval process for Nuceiva
8 February 2022 - Evolus today announced the acceptance of its submission to the Australian TGA for regulatory approval of Nuceiva ...
Posted by Michael Wonder on 09 Feb 2022
Women in Dobell can’t afford medicine
8 February 2022 - A third of women living in the federal electorate of Dobell struggle to afford prescription medicines, ...
Posted by Michael Wonder on 09 Feb 2022
More than 100 people a year in England could benefit from new endometrial cancer treatment within the Cancer Drugs Fund
8 February 2022 - Innovative new drug for treating endometrial cancer in adults recommended by NICE as an option for use ...
Posted by Michael Wonder on 08 Feb 2022
CVS adds Eliquis, other vital drugs to formulary exclusions
8 February 2022 - For eight years, Beth Joyner Waldron has counted on Eliquis to treat clots in her lungs ...
Posted by Michael Wonder on 08 Feb 2022
Three million Novavax doses touch down in Australia ahead of final TGA approval
8 February 2022 - Millions of Novavax vaccinations have arrived in Australia giving the country a new weapon against COVID-19. ...
Posted by Michael Wonder on 08 Feb 2022
NICE misses golden opportunity to enhance access to innovative cancer drugs
7 February 2022 - Cancer patients will miss out on exciting new treatments after NICE passed up a golden opportunity ...
Posted by Michael Wonder on 08 Feb 2022
Free EpiPen campaign returns in response to overwhelming demand
8 February 2022 - Allergy New Zealand and Pub Charity have relaunched the successful FundaPen campaign to deliver 3,355 free lifesaving ...
Posted by Michael Wonder on 08 Feb 2022
Leqvio therapy to lower cholesterol approved by FDA, IVX Health now accepting new Leqvio patients
8 February 2022 - IVX Health, a national provider of infusion and injection therapy for patients with complex chronic conditions, ...
Posted by Michael Wonder on 08 Feb 2022
EMA evaluating data on booster dose of COVID-19 vaccine Comirnaty in adolescents
8 February 2022 - EMA has started evaluating an application for the use of a booster dose of Comirnaty (BioNTech/Pfizer’s vaccine) ...